28,185 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Bought by Systematic Financial Management LP

Systematic Financial Management LP purchased a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 28,185 shares of the specialty pharmaceutical company's stock, valued at approximately $879,000. Systematic Financial Management LP owned 0.05% of Supernus Pharmaceuticals at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. GAMMA Investing LLC raised its stake in shares of Supernus Pharmaceuticals by 97.1% during the 3rd quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company's stock worth $25,000 after acquiring an additional 398 shares in the last quarter. Meeder Asset Management Inc. acquired a new position in shares of Supernus Pharmaceuticals in the second quarter valued at about $47,000. Innealta Capital LLC purchased a new stake in shares of Supernus Pharmaceuticals in the 2nd quarter valued at $51,000. Mirae Asset Global Investments Co. Ltd. lifted its position in Supernus Pharmaceuticals by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company's stock valued at $61,000 after purchasing an additional 352 shares during the period. Finally, nVerses Capital LLC purchased a new position in Supernus Pharmaceuticals during the second quarter valued at approximately $72,000.

Insiders Place Their Bets

In other Supernus Pharmaceuticals news, SVP Frank Mottola sold 15,000 shares of the business's stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $36.98, for a total value of $554,700.00. Following the completion of the sale, the senior vice president now owns 8,200 shares in the company, valued at approximately $303,236. The trade was a 64.66 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Georges Gemayel sold 14,213 shares of the firm's stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $36.62, for a total transaction of $520,480.06. Following the transaction, the director now owns 13,315 shares in the company, valued at approximately $487,595.30. This trade represents a 51.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 154,213 shares of company stock worth $5,660,180 over the last 90 days. Corporate insiders own 9.30% of the company's stock.

Supernus Pharmaceuticals Price Performance

NASDAQ SUPN traded up $0.18 during trading hours on Friday, hitting $37.17. 220,367 shares of the company's stock traded hands, compared to its average volume of 327,726. The firm's 50-day moving average is $34.84 and its 200-day moving average is $31.60. Supernus Pharmaceuticals, Inc. has a 52-week low of $25.53 and a 52-week high of $39.37. The company has a market capitalization of $2.05 billion, a PE ratio of 34.74 and a beta of 0.90.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share for the quarter, topping analysts' consensus estimates of $0.44 by $0.25. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. The business had revenue of $175.70 million during the quarter, compared to analysts' expectations of $157.35 million. During the same period in the prior year, the business posted ($0.29) EPS. The company's revenue was up 14.2% compared to the same quarter last year. Equities research analysts predict that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have commented on SUPN. Cowen reissued a "buy" rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Piper Sandler reissued a "neutral" rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.